Robeco Institutional Asset Management B.V. Has $71.35 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Robeco Institutional Asset Management B.V. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 112,495 shares of the biopharmaceutical company's stock after selling 16,813 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.10% of Regeneron Pharmaceuticals worth $71,348,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the last quarter. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the period. Finally, Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock remained flat at $521.00 during mid-day trading on Friday. 1,607,735 shares of the company were exchanged, compared to its average volume of 897,423. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a market capitalization of $56.25 billion, a P/E ratio of 13.26, a price-to-earnings-growth ratio of 1.91 and a beta of 0.31. The company has a fifty day simple moving average of $555.02 and a 200-day simple moving average of $634.70. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the business posted $9.55 EPS. The business's quarterly revenue was down 3.7% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.68%. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on REGN. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. UBS Group decreased their price target on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research report on Thursday, June 5th. Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Royal Bank Of Canada lowered shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a research report on Friday, May 30th. Finally, Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $700.00 to $580.00 in a research note on Friday, May 30th. One analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $822.58.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.